Skip to main content
Lexeo Therapeutics, Inc. logo

Lexeo Therapeutics, Inc. — Investor Relations & Filings

Ticker · LXEO ISIN · US52886X1072 US Manufacturing
Open in API
Filings indexed 289 across all filing types
Latest filing 2024-11-13 Director's Dealing
Country US United States of America
Listing US LXEO

About Lexeo Therapeutics, Inc.

https://www.lexeotx.com/

Lexeo Therapeutics, Inc. is a clinical-stage genetic medicine company dedicated to developing gene therapies for genetically defined diseases. The company is advancing a diverse pipeline of investigational adeno-associated virus (AAV)-based gene therapy candidates. Its primary areas of focus are rare cardiovascular diseases and APOE4-associated Alzheimer's disease. Lexeo's strategy centers on addressing conditions with high unmet medical needs by leveraging pioneering science, including research originating from institutions such as Weill Cornell Medicine, to develop treatments with curative potential.

Recent filings

Filing Released Lang Actions
Director's Dealing 2024
Director's Dealing
2024-11-13 English
Director's Dealing 2024
Director's Dealing
2024-11-13 English
424B3
Interim / Quarterly Report Classification · 100% confidence The document is a Form 10-Q Quarterly Report filed with the SEC for the quarterly period ended September 30, 2024. It includes detailed financial statements such as balance sheets, statements of operations, cash flows, notes to financial statements, and management's discussion and analysis. The document is about 15,000 characters long, indicating it is a full report rather than a brief announcement. The presence of unaudited financial statements and the quarterly period reference confirms it is an Interim / Quarterly Report. Therefore, the correct classification is 'IR'.
2024-11-13 English
10-Q
Interim / Quarterly Report 9M 2024
2024-11-13 English
424B3
Capital/Financing Update Classification · 95% confidence The document is a Form 8-K Current Report filed with the SEC, dated November 13, 2024, by Lexeo Therapeutics, Inc. It includes a prospectus supplement related to a registration statement and updates on a private placement and registration rights agreement. The report also announces the appointment of a new director to the board and furnishes a press release with financial results for the three and nine months ended September 30, 2024. The document contains no full financial statements or comprehensive financial analysis typical of an Interim/Quarterly Report (IR) but rather provides updates on capital raising and management changes. The primary content is the announcement of a director appointment and a capital raising update through a prospectus supplement. Given the combination of capital raising information and management/board changes, the classification that best fits is Capital/Financing Update (CAP) due to the detailed prospectus supplement on share registration and private placement, with a secondary element of management change. However, since the document includes significant detail on the share offering and registration, CAP is the most appropriate classification. Confidence is high due to the clear presence of a prospectus supplement and registration statement details, which are definitive indicators of capital/financing activity.
2024-11-13 English
8-K
Board/Management Information Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated November 11, 2024, by Lexeo Therapeutics, Inc. It includes two main items: Item 2.02 which reports the results of operations and financial condition via a press release for the three and nine months ended September 30, 2024, and Item 5.02 which announces the appointment of a new director to the board. The document is not a full financial report but a current report disclosing specific events. The appointment of a new director is a change in senior management/board. The financial results are referenced via a press release, not the full earnings release itself. The primary new information is the director appointment. Therefore, the best classification is Board/Management Information (MANG).
2024-11-13 English

Browse filings by year

5 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.